Navigation

Leukaemia (chronic myeloid) - Dasatinib, nilotinib, imatinib (intolerant, resistant) (including partial review of TA70)

Leukaemia (chronic myeloid) - Dasatinib, nilotinib, imatinib (intolerant, resistant) (including partial review of TA70)

Status: History
Expected date of issue: September 2011
Process: MTA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Scott Goulden
Communications manager: Alice Law
Project manager: Lori Farrar
Top


 

Provisional schedule

1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Bristol-Myers Squibb (dasatinib)
  • Novartis Pharmaceuticals (imatinib, nilotinib)

Patient/carer groups

  • Chronic Myeloid Leukaemia Support Group
  • Leukaemia CARE
  • Macmillan Cancer Support

Professional groups

  • British Committee for Standards in Haematology
  • British Society for Haematology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government
  • Wiltshire PCT

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • Bristol-Myers Squibb  (hydroxycarbamide)
  • MSD Ltd (interferon alpha)
  • Novartis (imatinib)

Relevant research groups

  • Leukaemia & Lymphoma Research
  • Leukaemia Research Fund

Assessment Group

  • National Institute for Health Research Health Technology Assessment
  • Peninsula Technology Assessment Group, University of Exeter (PenTAG)
  • Southampton Health Technology Assessment Centre

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
2 August 2011 Following the Appraisal Committee meeting held on 9 June, a Final Appraisal Determination (FAD) will be released.  At present the release of the FAD has been delayed and NICE are working to finalise the timings for release.
12 July 2011 In July 2010, the Final  Appraisal Determination recommendations for dasatinib and nilotinib in people with  imatinib-intolerant chronic myeloid leukaemia were not issued as planned, it was thought the recommendations could be influenced by the outcome of the appraisal for people with  imatinib-resistant chronic myeloid leukaemia. The release of the FAD was therefore delayed until the release of the FAD for dasatinib, nilotinib and high-dose imatinib in people with imatinib-resistant chronic myeloid leukaemia – this topic was discussed at the Appraisal Committee C meeting on Thursday 9 June 2011. Following the Appraisal Committee discussion on 9 June, NICE will release one FAD combining the recommendations for both people with imatinib-resistant chronic myeloid leukaemia and with imatinib-intolerant chronic myeloid leukaemia.  The appraisal will now be titled as Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (part review TA70) and dasatinib and nilotinib for people with chronic myeloid leukaemia for whom treatment with imatinib has failed because of intolerance.
Top


 

Key documents

This page was last updated: 10 January 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.